Stay updated with breaking news from Lin Guey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility,...
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
The firms are to evaluate Carsgen's autologous CAR T-cell therapy CT041 with Moderna's off-the-shelf mRNA vaccine candidate in preclinical and Phase I studies.
The companies will evaluate Moderna’s investigational Claudin18.2 mRNA cancer vaccine in combination with CARsgen’s Claudin18.2 CAR T cell candidate.
A Chinese biotech, CARsgen Therapeutics and Moderna Inc (NASDAQ: MRNA) have collaborated